The Vaccines Related Biological Products Advisory Committee to the Food and Drug Administration voted unanimously to recommend a monovalent JN.1-lineage as the 2024 vaccine against SARS-CoV-2.  This decision was based on epidemiologic studies indicating the predominance JN.1. 

Manufacturers of vaccine for 2024-2025 will follow the FDA requirement with the updated vaccine available during the fall.  The adoption of mRNA technology for COVID vaccines allows for rapid selection of this strain to optimize antigenicity.

Moderna is currently testing a bivalent COVID and influenza mRNA vaccine that would prove convenient if approved to establish immunity to both of the seasonal strains of the diseases as a single dose administered each fall.